Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled withKRASmutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis
Authors:
- A. SouqueASA. Souque
- P. SenessePSP. Senesse
- E. AssenatEAE. Assenat
- M. BarthetMBM. Barthet
- N. LesavreNLN. Lesavre
- A. AubertAAA. Aubert
- D. O'TooleDOD. O'Toole
- P. HammelPHP. Hammel
- P. LevyPLP. Levy
- P. RuszniewskiPRP. Ruszniewski
- M. BouissonMBM. Bouisson
- 16 June 2009
- journal article
- research article
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 41 (06) , 552-557
Abstract
Background and study aims: Differential diagnosis between pancreatic adenocarcinoma (PADC) and pseudotumoral forms of chronic pancreatitis remains difficult. Mutation of KRAS oncogene is present in 75 % to 95 % of PADC. This study aimed to evaluate whether the combined analysis of KRAS mutation with cytopathological findings from endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB) might improve discrimination between PADC and chronic pancreatitis. Patients and methods: This prospective multicenter study included 178 patients with solid pancreatic masses (men 104, women 74; mean age 64.5 years). Cytopathological examination and KRAS mutation analysis (codon-12 and codon-13, restriction fragment length polymorphism [RFLP] and direct sequencing) were performed on EUS-FNAB material. Final diagnoses were obtained on EUS-FNAB analysis and/or a second biopsy and/or clinical follow-up and/or surgery: PADC, n = 129; chronic pancreatitis, n = 27; other pancreatic neoplasms, n = 16; and benign lesions, n = 6. Results: KRAS status analysis was successful in all EUS-FNAB samples. Codon-12 KRAS point mutation was found in 66 % of PADC samples. No case of chronic pancreatitis displayed KRAS mutation. Sensitivity, specificity, positive and negative predictive values, and overall accuracy of cytopathology alone for diagnosis of PADC versus chronic pancreatitis were 83 %, 100 %, 100 %, 56 % and 86 %, respectively. When KRAS mutation analysis was combined with cytopathology, these values reached 88 %, 100 %, 100 %, 63 % and 90 % respectively. Conclusion: Although the value of KRAS analysis in addition to EUS-FNAB is limited for distinguishing pancreatic mass lesions, when chronic pancreatitis presented as a pseudotumor a negative finding (wild-type KRAS), was useful in strongly suggesting a benign lesion.Keywords
This publication has 15 references indexed in Scilit:
- Indications and limitations of endoscopic ultrasound elastography for evaluation of focal pancreatic lesionsEndoscopy, 2008
- A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video)Gastrointestinal Endoscopy, 2008
- EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurementGastrointestinal Endoscopy, 2007
- EUS elastography of the pancreas: feasibility and pattern description of the normal pancreas, chronic pancreatitis, and focal pancreatic lesionsGastrointestinal Endoscopy, 2007
- Endoscopic Ultrasound Fine Needle Aspirate DNA Analysis to Differentiate Malignant and Benign Pancreatic MassesAmerican Journal of Gastroenterology, 2006
- Early Morbidity of Endoscopic Ultrasound: 13 Years’ Experience at a Referral CenterEndoscopy, 2006
- Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitisGastrointestinal Endoscopy, 2005
- Endoscopic ultrasound-guided fine-needle aspiration cytology for diagnosis above and below the DiaphragmJournal of Clinical Ultrasound, 2005
- Predictive Factors for Pancreatic Cancer in Patients with Chronic Pancreatitis in Association with K-rasGene MutationEndoscopy, 2004
- Clinical impact of on-site cytopathology interpretation on endoscopic ultrasound-guided fine needle aspirationAmerican Journal of Gastroenterology, 2003